Literature DB >> 28363444

Discovery of a series of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton as potential FAK inhibitors.

Juan Sun1, Shen-Zhen Ren2, Xiao-Yuan Lu2, Jing-Jing Li2, Fa-Qian Shen2, Chen Xu3, Hai-Liang Zhu4.   

Abstract

Focal adhesion kinase (FAK) is an important drug target that plays a fundamental role in mediating signal transduction system. We report herein the discovery of a novel class of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton with improved potency toward FAK. All of the 17 new synthesized compounds were assayed for the anticancer activities against four cancer cells, HepG2, Hela, SW116 and BGC823. Because of the combination of 1,4-benzodioxan, 1,3,4-oxadiazole and piperazine ring, most of them exhibited remarkable antitumor activities. Notably, compound 5m showed the most potent biological activities (IC50=5.78μM for HepG2, and IC50=47.15μM for SW1116), and its anti-FAK inhibitory activity (IC50=0.78μM) was also the best. Computational docking studies also showed that compound 5m has interaction with FAK key residues in the active site.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antitumor activity; Benzodioxan; FAK; Oxadiazoles; Piperazine

Mesh:

Substances:

Year:  2017        PMID: 28363444     DOI: 10.1016/j.bmc.2017.03.038

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

Review 1.  The Development of FAK Inhibitors: A Five-Year Update.

Authors:  Andrea Spallarossa; Bruno Tasso; Eleonora Russo; Carla Villa; Chiara Brullo
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

2.  Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights.

Authors:  Wagdy M Eldehna; Raed M Maklad; Hadia Almahli; Tarfah Al-Warhi; Eslam B Elkaeed; Mohammed A S Abourehab; Hatem A Abdel-Aziz; Ahmed M El Kerdawy
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

3.  Synthesis and biological evaluation of 3-(1,3,4-oxadiazol-2-yl)-1,8-naphthyridin-4(1H)-ones as cisplatin sensitizers.

Authors:  Xueyan Hou; Hao Luo; Mengqi Zhang; Guoyi Yan; Chunlan Pu; Suke Lan; Rui Li
Journal:  Medchemcomm       Date:  2018-09-25       Impact factor: 3.597

4.  1,3,4-Oxadiazole N-Mannich Bases: Synthesis, Antimicrobial, and Anti-Proliferative Activities.

Authors:  Lamya H Al-Wahaibi; Ahmed A B Mohamed; Samar S Tawfik; Hanan M Hassan; Ali A El-Emam
Journal:  Molecules       Date:  2021-04-07       Impact factor: 4.411

5.  Synthesis, Anticancer Activity and Molecular Docking Studies of Novel N-Mannich Bases of 1,3,4-Oxadiazole Based on 4,6-Dimethylpyridine Scaffold.

Authors:  Małgorzata Strzelecka; Teresa Glomb; Małgorzata Drąg-Zalesińska; Julita Kulbacka; Anna Szewczyk; Jolanta Saczko; Paulina Kasperkiewicz-Wasilewska; Nina Rembiałkowska; Kamil Wojtkowiak; Aneta Jezierska; Piotr Świątek
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

Review 6.  FAK inhibitors as promising anticancer targets: present and future directions.

Authors:  Muhamad Mustafa; Amer Ali Abd El-Hafeez; Dalia A Abdelhafeez; Dalia Abdelhamid; Yaser A Mostafa; Pradipta Ghosh; Alaa M Hayallah; Gamal El-Din A Abuo-Rahma
Journal:  Future Med Chem       Date:  2021-08-03       Impact factor: 4.767

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.